---
title: "Lysergide (DT120) in Generalized anxiety disorder: LDA1"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: LDA1. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 56 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence/lda1"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: LDA1

<a id="heading-3.1.5"></a>

## 3.1.5 LDA1

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Registered purpose

> “This study will find out whether psychotherapy combined with lysergic acid diethylamide (LSD) is safe and is helpful in people who are anxious because they have a potentially fatal disease.”
> “This study will examine whether two sessions of LSD-assisted psychotherapy scheduled two to four weeks apart will reduce anxiety and improve quality of life for people experiencing anxiety as a result of a potentially fatal illness.”

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.1-2"></a>

#### Published objective

> “A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases.”
> “The present LSD study was designed to evaluate previous findings applying current research methodology.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.1-3"></a>

#### Objective of the qualitative follow-up

> “Participants of this study were included in a prospective follow-up.”
> “A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and lasting psychological changes.”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Study identifiers, dates, and status

| Item | Registry record |
| --- | --- |
| Other study ID | “LDA1” |
| Phase | “Phase 2” |
| Study start | “2008-02” |
| Primary completion (actual) | “2011-04-14” |
| Study completion (actual) | “2012-09” |
| First posted (estimated) | “2009-06-15” |
| Results first posted | “2021-12-08” |
| Last update posted | “2023-07-12” |

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.2-2"></a>

#### Site: one private practice in Switzerland

> “This study has 1 location”
> “Solothurn, Switzerland Private Practices of Peter Gasser MD”
> “Sponsor Multidisciplinary Association for Psychedelic Studies”

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.2-3"></a>

#### Recruitment and visit period as published

> “Recruitment took place from 2007 to 2011 until all planned participants were enrolled, and study visits were completed from 2008 to 2012.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Official title and registered design

> “LSD-assisted Psychotherapy in Persons Suffering From Anxiety Associated With Advanced-stage Life Threatening Diseases. A Phase-II, Double-blind, Placebo-controlled Dose-response Pilot Study”
> “This study will be a randomized, active placebo controlled,double-blind pilot study of the safety and efficacy of LSD-assisted psychotherapy as a way of reducing anxiety in people with potentially fatal illnesses.”
> “The randomized part of the study will last three and a half months (14 weeks).”

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

| Design element | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.3-2"></a>

#### Active placebo control and open-label crossover

> “This phase 2 double-blind, active placebo-controlled, randomized clinical trial”
> “Two months after the second experimental session, a follow-up evaluation was completed, and the treatment period was finished by breaking the blind for each individual. The participants who received the active placebo could cross over to an identical but open-label treatment with 200 μg of LSD. A long-term follow-up evaluation was conducted 12 months after the last experimental session with LSD in either the blinded portion of the study or the open-label crossover.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.3-3"></a>

#### Ethics and regulatory approvals

> “was approved by the Ethics Committee of the Canton of Aargau, Swissmedic, the Swiss Federal Office for Public Health (Bundesamt fuer Gesundheit [Swiss Ministry of Health]), and the US Food and Drug Administration (Investigational New Drug no. 101,825) and was conducted in accordance with Good Clinical Practices.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.3-4"></a>

#### Funding and sponsor

> “This study was funded in part by Schweizerische Aerztegesellschaft für Psycholytische Therapie (Swiss Medical Society for Psycholytic Therapy) and Multidisciplinary Association for Psychedelic Studies. Rick Doblin (president) and Berra Yazar-Klosinski are employees of the main sponsor MAPS. Peter Gasser is president of SAEPT.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.3-5"></a>

#### Qualitative follow-up design

> “12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview.”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Inclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Life-threatening illness | “Have a diagnosis of advanced-stage potentially fatal illness.” |
| Illness types | “As well as metastatic cancer this may include autoimmune, neurological, infectious or rheumatoid diseases as well.” |
| Survival | “The participant must have a probability of survival of more than six months.” |
| Anxiety diagnosis or severity | “Meet DSM-IV criteria for Anxiety Disorder as indicated by the SCID or have a score of at least 40 on each part of the STAI.” |
| Prior treatment | “Have failed to respond adequately or at all to medication or psychotherapy intended to reduce anxiety, or have refused to take anxiolytic medication.” |
| Other affective disorders | “May be diagnosed with another affective disorder other than anxiety disorder, except bipolar-I disorder.” |
| Age | “Are at least 18 years of age.” |
| Psychiatric medication | “Are willing to withdraw from taking any psychiatric medications during the experimental session period.” |
| Washout | “Drugs must be discontinued long enough before the first LSD treatment session to avoid the possibility of a drug-drug interaction (the interval will be at least 5 times the particular drug's half-life).” |

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.4-2"></a>

#### Exclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Pregnancy and contraception | “Women who are pregnant or nursing, or of child bearing potential and are not practicing an effective means of birth control.” |
| Psychotic disorder | “Anyone with past or present diagnosis with a primary psychotic disorder.” |
| Dissociative or bipolar disorder | “Meeting DSM-IV criteria for Dissociative Disorder or Bipolar-I Affective Disorder.” |
| Substance use | “Meeting DSM-IV criteria for abuse of or dependence on any substance (other than caffeine or nicotine) in the past 60 days.” |
| Liver function | “No sufficient liver function at the baseline examination or the day before the experimental sessions.” |
| Central nervous system involvement | “Having evidence of CNS affection from the primary disease (e.g. brain metastasis), shown by neurocognitive impairment.” |
| Body weight | “Weighing less than 45 kg.” |
| Suicide risk | “Reasonably judged to present a serious suicide risk or who are likely to require psychiatric hospitalization during the course of the study.” |
| Concomitant psychotropic therapy | “Requiring ongoing concomitant therapy with a psychotropic drug (other than as needed, anxiety medications, and pain control medications) and are unable or unwilling to comply with the washout period.” |

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.4-3"></a>

#### Eligibility as published: STAI threshold and exclusions

> “Individuals with current alcohol or drug dependence (except caffeine or nicotine); primary psychotic, bipolar I affective, or dissociative disorders; and neurocognitive impairment and women who were pregnant or nursing were excluded from this study. All participants reported a score of greater than 40 on either the state or the trait scale of the Spielberger State-Trait Anxiety Inventory”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.4-4"></a>

#### Recruitment

> “The participants were recruited through general information about the study reported in media, by flyers, presentations in hospitals or cancer support groups, or referral from other physicians.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Registered treatment arms

| Arm | Quoted registry text |
| --- | --- |
| Full dose LSD | “200 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.” |
| Active placebo LSD | “20 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.” |
| Therapy | “Therapy provided by male and female co-therapists” |
| Randomization ratio | “Subjects in this study will have a 66% of receiving the full dose of 200 mcg LSD, and they have a 33% chance of getting the active placebo dose of 20 mcg LSD.” |

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.5-2"></a>

#### Study drug: LSD free base capsules

> “LSD was supplied as free base by Lipomed (Arlesheim, Switzerland). Capsules consisting of 200 μg (experimental dose) and 20 μg of LSD (active placebo) were prepared by Bichsel Laboratories (Interlaken, Switzerland).”
> “Capsules were of identical size, color, and shape and were bottled in sequentially numbered containers.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.5-3"></a>

#### Experimental sessions and dose selection

> “The primary intervention consisted of two full-day experimental sessions scheduled 2 to 3 weeks apart with a male/female co-therapist team, embedded within an ongoing process of drug-free psychotherapy sessions for preparatory and integrative purposes. The participants were randomly assigned to the experimental dose groups, receiving either an oral dose of 200 μg of LSD (n = 8) or an active placebo of 20 μg of LSD (n = 4). The experimental dose was a moderate amount expected to produce the full spectrum of a typical LSD experience, without fully dissolving normal ego structures. The 20-μg dose of LSD was chosen as an active placebo to produce short-lived, mild, and detectable LSD effects that would not substantially facilitate a therapeutic process.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.5-4"></a>

#### Session setting, duration, and psychotherapy

> “Two preparatory psychotherapy sessions served to discuss the participant’s history, social situation, personality, health, mind-set, and emotional situation”
> “Other than going to the bathroom, the participants remained in the treatment room for the entire 8-hour experimental session and overnight with an attendant nearby.”
> “The therapeutic session ended after 8 hours, when the acute effects had subsided, followed by a brief review of the day’s experiences. After each experimental session, three drug-free psychotherapy sessions lasting 60 to 90 minutes took place, during which the participant’s experiences were reviewed for integration and deepening the therapeutic process.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.5-5"></a>

#### Concomitant medications and restrictions

> “The participants were required to taper off of antidepressants and antianxiety medications, to avoid alcohol and recreational drugs for 24 hours before, and to abstain from driving for 24 hours after the experimental sessions.”
> “During the study, two participants (both experimental dose) received concomitant selective serotonin reuptake inhibitor (SSRI) treatment for depression and tapered off of these medications five half-lives before each experimental session because SSRIs may attenuate the effects of the serotonergically active experimental drug”
> “Three participants received benzodiazepines (two experimental dose and one active placebo) as needed.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using State-Trait Anxiety Inventory Score as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### STAI as the primary outcome measure

> “The STAI Form X, a widely used self-report instrument for assessing state and trait anxiety in adults, served as the primary outcome measure of anxiety symptoms.”
> “Outcome measures were completed at baseline, 1 week after experimental sessions, 2-month follow-up, and 12-month follow-up.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.6.1-2"></a>

##### Registered primary outcome and scale description

> “Primary Endpoint State-Trait Anxiety Inventory (STAI)”
> “The STAI-state subscale is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety.”
> “STAI-state scores are summed for a total score that range from 20 to 80, with higher scores indicating greater state anxiety. The STAI-trait subscale also consists of 20-items and is scored the same way, with total scores ranging from 20 to 80, with higher scores indicating greater trait anxiety.”
> “2 months after second experimental session”

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.6.1-3"></a>

##### Trait anxiety as an outcome

> “Trait anxiety is not expected to be altered by short-term psychotherapy”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.6.1-4"></a>

##### Secondary outcome measures

> “Secondary outcome measures included the European Cancer Quality of Life Questionnaire 30-item version 1.0”
> “the SCL-90-R”
> “and the Hospital Anxiety and Depression Scale”
> “After each experimental session, the State of Consciousness Questionnaire was completed”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Screened, enrolled, and randomized

> “Of 70 participants who were evaluated for eligibility by telephone or e-mail, 20 were further screened in person, and 12 were enrolled in this study”
> “The participants received either 200 μg of LSD (n = 8) or 20 μg of LSD with an open-label crossover to 200 μg of LSD after the initial blinded treatment was unmasked (n = 4).”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

> “Enrollment (Actual) 12”

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.7.1-2"></a>

##### Analyzed: 8 and 3 participants

> “One active placebo participant was excluded from analysis after completing all study procedures because of a correction in the diagnosis of the qualifying disease state, which no longer satisfied the inclusion criteria.”
> “Values are mean ± SEM of changes from baseline in eight subjects in the LSD group and three subjects in the placebo group.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.7.1-3"></a>

##### Sample size basis

> “As a pilot study, this study had limited sample size, which reduced precision in effect size estimates and significance testing. The sample size selected was sufficient for a study primarily focused on safety and feasibility.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.7.1-4"></a>

##### Participants assessed at 12 months in the qualitative follow-up

> “12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview.”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Statistical methods and multiplicity

> “Repeated-measures analysis of variance (ANOVA) was used to test for significant changes in anxiety from baseline to subsequent posttreatment measurements. STAI trait and STAI state were analyzed in separate ANOVAs. To account for multiplicity, the alpha level indicating significance was adjusted to 0.025 (two tailed). Effect sizes were estimated using Cohen’s d techniques. Results of the 12-month follow-up were compared with those of the 2-month follow-up with paired t-tests. Secondary outcome measures conducted for exploratory purposes were not used for significance testing to reduce multiplicity.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.7.2-2"></a>

##### Handling of missing data and exclusion from analysis

> “We were unable to obtain results for two subjects (one experimental dose, one active placebo) from the assessment conducted 1 week after the second experimental session because of intervening cancer treatments. To avoid substantially reducing the sample size because of missing data, the assessment 1 week after the second experimental session was dropped for all subjects from analysis of outcomes. One active placebo participant was excluded from analysis after completing all study procedures because of a correction in the diagnosis of the qualifying disease state, which no longer satisfied the inclusion criteria.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Registry participant flow

| Period and status | Full dose LSD (200 mcg), blinded stage 1 | Active placebo LSD (20 mcg), stage 1 | Full dose LSD (200 mcg), open-label stage 2 |
| --- | --- | --- | --- |
| Stage 1 started | “8” | “4” | “0” |
| Stage 1 completed | “7” | “4” | “0” |
| Stage 1 not completed: adverse event | “1” | “0” | “0” |
| Stage 2 started | “0” | “0” | “3” |
| Stage 2 completed | “0” | “0” | “3” |

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.1-2"></a>

##### Crossover to open-label treatment

> “The crossover group (n = 3) shows a positive trend of STAI state and trait score reduction.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Registry baseline characteristics

| Characteristic | Full dose LSD (200 mcg) | Active placebo LSD (20 mcg) | Total |
| --- | --- | --- | --- |
| Participants | “8” | “3” | “11” |
| Age, years, mean (SD) | “49.6(8.4)” | “57.4(9.9)” | “51.7(9.1)” |
| Female | “3” | “1” | “4” |
| Male | “5” | “2” | “7” |
| History of suicidal tendencies: none | “8” | “1” | “9” |
| History of suicidal tendencies: mild | “0” | “2” | “2” |
| Metastatic breast carcinoma | “3” | “1” | “4” |
| Metastatic gastric carcinoma | “2” | “0” | “2” |
| Plasmocytoma | “1” | “0” | “1” |
| Non-Hodgkin's Lymphoma | “0” | “1” | “1” |
| Celiac Disease | “0” | “1” | “1” |
| Parkinson's Disease | “1” | “0” | “1” |
| Bechterew's Disease | “1” | “0” | “1” |

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.2-2"></a>

##### Baseline STAI scores (registry primary outcome at baseline, visit 4)

| STAI subscale, mean (SD) | Full dose LSD (200 mcg), n = 8 | Active placebo LSD (20 mcg), n = 3 |
| --- | --- | --- |
| STAI-state | “53.1(4.7)” | “47.7(7.7)” |
| STAI-trait | “53.2(4.3)” | “43.3(7.0)” |

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.2-3"></a>

##### Race and ethnicity not collected

> “Race and Ethnicity were not collected from any participant.”

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.2-4"></a>

##### Diagnoses and prior LSD experience

> “Eleven of the 12 subjects had no prior experience with LSD.”
> “half of the subjects were diagnosed with generalized anxiety disorder (GAD).”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.2-5"></a>

##### Baseline comparability of STAI scores

> “No significant difference was found (p = 0.261) between group mean scores at baseline.”
> “No significant difference was found between the groups at baseline (p = 0.563).”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Primary endpoint: STAI at 2 months after the second session (registry)

| STAI subscale, mean (SD) | Full dose LSD (200 mcg), n = 8 | Active placebo LSD (20 mcg), n = 3 |
| --- | --- | --- |
| STAI-state | “41.5(3.2)” | “51.7(5.3)” |
| STAI-trait | “45.2(3.7)” | “49.0(6.1)” |

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.3-2"></a>

##### Primary endpoint: published analysis

> “At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.3-3"></a>

##### Trait anxiety

> “The visit × group interaction testing for differences between the groups produced p = 0.033 (F = 4.151, df = 2,18), and observed statistical power was 65.6%, with results trending toward statistical significance. Comparing trait anxiety at baseline with 2-month follow-up yielded an effect size of 1.1. However, only three of eight experimental dose subjects dropped lower than the threshold value of 40 after the intervention. In contrast, all active placebo subjects experienced increases in trait anxiety.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.3-4"></a>

##### State anxiety

> “The visit × group interaction testing for differences between the groups produced p = 0.021 (F = 4.846, df = 2,18), and observed statistical power was 72.7%. Even controlling for multiplicity, the reductions in state anxiety were statistically significant 2 months after two experimental sessions of LSD-assisted psychotherapy. Comparing state anxiety at baseline with 2-month follow-up yielded an effect size of 1.2. However, only three of eight experimental dose subjects dropped lower than the diagnostic cutoff of 40 after the intervention. In contrast, two active placebo subjects experienced increases in state anxiety.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.3-5"></a>

##### Durability at 12 months

> “Comparison of 2-month and 12-month follow-up results in the subjects who received 200 μg of LSD in either the blinded sessions or the open-label crossover indicate that the benefits were sustained over time. The mean difference varied only by 0.667 between these assessments, and no significant difference was found with p = 0.825 (two tailed).”
> “Comparison of 2-month and 12-month follow-up results in the subjects who received 200 μg of LSD in either the blinded sessions or the open-label crossover indicates that the benefits were sustained over time. The mean difference varied only by 1.00 between these assessments, and no significant difference was found with p = 0.531 (two tailed).”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

> “The significant benefits as measured with the STAI were sustained over a 12-month period.”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="topic-3.1.5.8.3-6"></a>

##### Hospital Anxiety and Depression Scale

> “The experimental dose group mean (SD) anxiety scores decreased from 11.7 (3.4) to 8.1 (3.2) after two sessions, whereas the active placebo group anxiety scores decreased only from 11.3 (2.1) to 10.7 (3.0). The active placebo subjects who continued to the crossover experienced an even greater decline lower than the diagnostic cutoff for anxiety to 7.0 (2.6). All subjects who received the experimental dose were lower than the diagnostic cutoff at the 12-month follow-up, with a mean (SD) of 7.6 (4.5). The depression results also mirrored the anxiety results.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

##### Quality of life: EORTC-QLQ global health score

> “Global health scores from the EORTC-QLQ increased from a mean (SD) of 37.4 (10.0) at baseline to 50.0 (14.9) after treatment with two sessions of 200 μg of LSD, whereas mean scores decreased from 44.3 (12.7) to 36.0 (12.8) in the active placebo group.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.4-2"></a>

##### General psychopathology: SCL-90-R Global Severity Index

> “Global Severity Index (GSI) scores from the SCL-90-R decreased from a mean (SD) T-score of 69.6 (6.7) at baseline to 60.2 (7.2) in the experimental dose group whereas increasing from 66.0 (15.1) to 67.7 (10.2) in the active placebo group. The active placebo group experienced an improvement comparable with the full-dose group after receiving the experimental dose in the open-label crossover, with mean (SD) T-scores dropping to 57.3 (15.0).”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.4-3"></a>

##### Participant-reported changes at 12 months (qualitative content analysis)

> “In the QCA participants consistently reported insightful, cathartic and interpersonal experiences, accompanied by a reduction in anxiety (77.8%) and a rise in quality of life (66.7%).”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Severe and related adverse events as published

> “Neither the experimental dose (200 μg of LSD) nor the active placebo (20 μg of LSD) produced any drug-related severe adverse events, that is, no panic reaction, no suicidal crisis or psychotic state, and no medical or psychiatric emergencies requiring hospitalization.”
> “The experimental dose subjects experienced more types of AEs (n = 18) than the active placebo subjects (n = 8). In general, AEs were reported more frequently and with increased intensity in the experimental dose sessions. Interestingly, fewer reports of anxiety were received during experimental sessions with 200 μg (22.7%) than with active placebo (50%), and the mean intensity of anxiety was comparable between the groups. However, the subjects reported experiencing mild-to-moderate emotional distress similarly in experimental dose sessions (36.4%) and active placebo sessions (33.3%). Most AEs resolved when drug effects diminished. Only six reports of mild related AEs (illusions, feeling cold or abnormal, and some emotional distress) persisted until the next day. No flashback phenomena or other prolonged effects were observed.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.5-2"></a>

##### Vital signs and rescue medication

> “LSD did not significantly alter blood pressure or heart rate”
> “Three participants received pain medication during the study, only one of which was required as rescue medication for a treatment-emergent AE. Acetaminophen was required for this participant for a moderate headache the day after an experimental dose session.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.5-3"></a>

##### Registry adverse events: mortality, serious, and selected other adverse events

> “From enrollment to end of Stage 2 (approximately 11 months)”
> “Indicates events were collected by non-systematic assessment”

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

| Adverse event (affected / at risk) | Full dose LSD (200 mcg), stage 1 | Active placebo LSD (20 mcg), stage 1 | Full dose LSD (200 mcg), stage 2 |
| --- | --- | --- | --- |
| All-cause mortality | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Serious adverse events, total | “1/8 (12.50%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Serious: metastatic esophageal cancer | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Serious: pyelonephritis | “0/8 (0.00%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Other adverse events, total | “8/8 (100.00%)” | “4/4 (100.00%)” | “3/3 (100.00%)” |
| Feeling cold | “6/8 (75.00%)” | “0/4 (0.00%)” | “1/3 (33.33%)” |
| Illusions | “6/8 (75.00%)” | “1/4 (25.00%)” | “2/3 (66.67%)” |
| Emotional distress | “5/8 (62.50%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Feeling abnormal | “5/8 (62.50%)” | “2/4 (50.00%)” | “1/3 (33.33%)” |
| Time perception altered | “4/8 (50.00%)” | “0/4 (0.00%)” | “2/3 (66.67%)” |
| Mydriasis | “3/8 (37.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Anxiety | “2/8 (25.00%)” | “2/4 (50.00%)” | “1/3 (33.33%)” |
| Impaired gait | “2/8 (25.00%)” | “0/4 (0.00%)” | “2/3 (66.67%)” |
| Hallucination | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.5-4"></a>

##### Long-term adverse reactions at 12 months

> “None of the participants reported lasting adverse reactions.”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary

LDA1 was a phase 2 pilot trial at one private practice in Solothurn, Switzerland, with the Multidisciplinary Association for Psychedelic Studies (MAPS) named as main sponsor; MAPS co-funded the trial, and the funding statement names two MAPS employees. Twelve participants with anxiety associated with life-threatening diseases were randomized to LSD 200 μg (8 participants) or an active placebo of LSD 20 μg (4 participants); one active placebo participant was excluded from analysis after a correction of the qualifying diagnosis, leaving 8 and 3 participants. The authors state that the sample size was sufficient for a study primarily focused on safety and feasibility and that the limited sample reduced precision in effect size estimates and significance testing.

With the alpha level adjusted to 0.025 for multiplicity, the reduction in state anxiety (p = 0.021) met the threshold and the reduction in trait anxiety (p = 0.033) did not. Only three of eight participants in the 200 μg group fell below the threshold of 40 on each subscale. The assessment 1 week after the second session was dropped for all participants because results were missing for two participants, and secondary outcomes were not tested for significance. The 12-month comparisons included participants who received 200 μg in the open-label crossover and had no concurrent control, and the qualitative follow-up tested 10 participants.

Blinding was not maintained: for all 24 blinded sessions, all participants correctly guessed the dose, and the authors state that the 20-μg dose was too low to achieve uncertainty about the dose. Half of the participants received a SCID diagnosis of generalized anxiety disorder, and the authors state that this does not mean the participants had the conventional pattern of psychopathology usually associated with GAD, because the SCID items do not differentiate GAD from a reaction to a life-threatening disease. The registry lists the illnesses as metastatic breast carcinoma (4 participants), metastatic gastric carcinoma (2), and plasmocytoma, non-Hodgkin's lymphoma, celiac disease, Parkinson's disease, and Bechterew's disease (1 each); mean age was 51.7 years, 7 of 11 participants were male, and race and ethnicity were not collected. The authors state that the course of the somatic illness may affect psychological parameters independent of the intervention, and that the EORTC-QLQ focused on physical aspects and was insufficient for evaluating long-term psychological changes.

The intervention combined LSD capsules with two preparatory psychotherapy sessions, three drug-free integrative psychotherapy sessions after each experimental session, and a male and female co-therapist team, with 8-hour experimental sessions and an overnight stay. The publication reports no drug-related severe adverse events; the registry reports serious adverse events of metastatic esophageal cancer (1 of 8) and pyelonephritis (1 of 4) and all-cause mortality of 1 of 8 in the 200 μg group. The registry and the publication differ on two details: the registry requires a score of at least 40 on each part of the STAI and spaces sessions two to four weeks apart, while the publication states that participants scored greater than 40 on either the state or the trait scale and that sessions were 2 to 3 weeks apart.

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/); [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/); [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387); [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.9-2"></a>

#### Limitations stated by the authors: sample size, blinding, and dose

> “As a pilot study, this study had limited sample size, which reduced precision in effect size estimates and significance testing.”
> “The imperfect blinding also limits the validity of the results.”
> “Although using a slightly higher LSD dose in the comparator group can increase blinding, it can also increase efficacy of the comparator, compromising the estimates of effect size. Given the safety of the moderate experimental dose, results might have been improved with a larger dose of 250 μg.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.9-3"></a>

#### Blinding assessment

> “For all 24 blinded sessions, all participants correctly guessed the dose of LSD that was administered, and both therapists guessed incorrectly in one active placebo session.”
> “This indicates that the 20-μg dose was too low to achieve successful uncertainty about the dose.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.9-4"></a>

#### Limitations stated by the authors: somatic illness and quality of life measure

> “Other limitations exist in treating participants with grave somatic diseases because the course of the somatic illness (e.g., worsening or improving) may substantially impact psychological parameters independent of the therapeutic intervention and contribute to missing data. The quality of life questionnaire (EORTC-QLQ), which was chosen as a secondary outcome measure, focuses extensively on physical aspects and was insufficient for evaluating long-term psychological changes.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.9-5"></a>

#### Applicability of the GAD diagnosis

> “Neither the SCID’s five items about GAD nor criterion E for GAD in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, differentiates between anxiety typically seen with GAD and a reaction to a life-threatening disease (and its consequences). Therefore, even though the SCID generates a diagnosis of GAD, this does not mean that the subjects had the conventional pattern of psychopathology usually associated with GAD.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.9-6"></a>

#### Number of sessions

> “Most of the participants stated a preference for more than two LSD sessions and a longer treatment period. The results demonstrated a decrease in STAI scores most prominently after the second LSD session, suggesting that at least two LSD sessions are needed to demonstrate these effects.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
